by Vora Corporate Finance | Oct 28, 2023 | Insights, Private Equity & IPO
Transaction: India Resurgence Fund (IndiaRF), promoted by Piramal Enterprises Limited and Bain Capital, Invested Rs. 525 Crores in Ivy Health and Life Sciences Private Limited (Ivy). The hospital is estimated to be valued at Rs 1100 Crores. About India Resurgence Fund...
by Vora Corporate Finance | Oct 28, 2023 | Insights, Merger & Acquisitions
Transaction: Glenmark Pharmaceuticals Limited (GPL) has entered into a share purchase agreement with Nirma Limited to divest a 75% stake in Glenmark Lifesciences (GLS) at an EV of Rs 7500 Crores. Current Promoter group to be public shareholders. About Glenmark...
by Vora Corporate Finance | Oct 28, 2023 | Insights
Secondary Market Update: Indian indices corrected marginally by Nifty 50 and Sensex gaining 2% at 19,638.30 and 1.04% at 65,508.32 respectively. In September, FPI sold total equities worth Rs 14,768 Crores. During September, despite of the global concerns and subdued...
by Vora Corporate Finance | Oct 28, 2023 | Insights
India’s inclusion in JP Morgan’s Emerging market bond index JP Morgan Chase & Co. in September said that it would include Indian Government Bond’s in its Government Bond Index- Emerging Markets Global Index Suite from June 2024. The inclusion of Indian Bonds in...
by Vora Corporate Finance | Oct 25, 2023 | Articles, Capital Market Updates
Fitch Ratings downgraded the United States of America’s Long-Term Rating to AA+ from AAA leading to increase in US treasury yields and sell off in US stock markets. There is a small note on credit rating agencies. Indian Indices hit all time high with Nifty 50 gaining...
